Role of human papillomavirus types 16, 18, and 52 in recurrent cystitis and urinary bladder cancer among Egyptian patients

MedGenMed Medscape General Medicine

Volumn 10, Issue 10, 2008, Pages

  Badawi, Hala ^a   Ahmed, Hanem ^b   Ismail, Ahmed ^c   Diab, Manal ^a   Moubarak, Magd ^a   Badawy, Afkar ^a   Saber, Mohamed ^b  

^a Imbaba   (Egypt)

^b Ministry of Scientific Research   (Egypt)

^c THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CYSTITIS; DNA DETERMINATION; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HOSPITAL PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; RECURRENT DISEASE; SCHISTOSOMIASIS; SEROLOGY; TRANSITIONAL CELL CARCINOMA; VIRUS CAPSID; BLADDER TUMOR; ISOLATION AND PURIFICATION; MIDDLE AGED; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; CYSTITIS; EGYPT; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RECURRENCE; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 54449094151     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. El-Bolkainy MN, Ghoneim MA, Mansour MA. Carcinoma of the bilharzial bladder in Egypt. Clinical and pathological features. Br J Urol. 1972;44:561-570.
2. Abdel-Salam IM, Khaled HM, Gabalah HB, et al. Tolemerase activity in bilharzial bladder cancer: prognostic implications. Urol Oncol. 2000;6:149-153.
3. Agliano AM, Gazzaniga P, Gradilone A, et al. Detection of human papillomavirus type 16 DNA sequences in paraffin-embedded tissues from the female urinary tract. Urol Int. 1994;52:208-212.
4. Bosch FX, Lorincx A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265.
5. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366:991-998.
6. Ferreccio C, Prado RB, Luzoro AV, et al. Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomark Prev. 2004;13:2271-2276.
7. Chang F, Lipponen P, Tervahauta A, et al. Transitional cell carcinoma of the bladder: failure to demonstrate human papillomavirus deoxyribonucleic acid by in situ hybridization and polymerase chain reaction. J Urol. 1994;152:1429-1433.
8. Anwar K, Naiki H, Nakakuki K, et al. High frequency of human papillomavirus infection in carcinoma of the urinary bladder. Cancer. 1992;70:1267-1273.
9. Zekri AR, El-Kabany M, Khaled HM. Concordance between PCR amplifiable HPV DNA and the presence of inclusion bodies in bilharzial bladder cancer among Egyptians. CMB. 1995;2:441-447.
10. Khaled HM, Bahnassi AA, Zekri AR. Correlation between p53 mutations and HPV in bilharzial bladder cancer. Urol Oncol. 2003;21:334-341.
11. De Gaetani C, Ferrari G, Righi E, et al. Detection of human papillomavirus DNA in urinary bladder carcinoma in situ hybridisation. J Clin Pathol. 1999;52:103-106.
12. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol. 1999;9:423-430.
13. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis. 1996; 174:927-936.
14. Bousarghin L, Combita-Rojas A-L, Touze A, et al. Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. J Clin Microbiol. 2000;40:926-932.
15. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle ELISA detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Nat Cancer Inst. 1994;86:494-499.
16. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. Available at: http://www.wma.net/e/policy/pdf/l7c.pdf Accessed September 4, 2008.
17. Flemming I, Cooper J, Henson D, et al. Urinary bladder. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven Publishers; 1997:241-246.
18. Ausubel MF, Brent R, Kingston RE, et al. Current Protocols in Molecular Biology. Vol (1):2.2.1. New York: Wiley Interscience; 1990.
19. Higuchi R. Simple and rapid preparation of samples for PCR. In: Erlich HA, ed. PCR Technology. Principles and Applications for DNA Amplification. New York: Stockton Press; 1989:31-38.
20. Shimada M, Fukushima M, Mukai H, et al. Amplification and specific detection of transforming gene region of human papillomavirus 16, 18 and 33 in cervical carcinoma by means of the polymerase chain reaction. Jpn J Cancer. 1990;81:1-5.
21. Seedorf K, Krammer G, Durst M, et al. Human papillomavirus type 16 DNA sequence. Virology. 1985;145:181-185.
22. Matsumoto K, Yoshikawa H, Yasugi T, et al. IgG antibodies to human papillornavirus, 16, 52, 58, and 6 Ll capsids: case-control study of cervical interaepithelial neoplasia in Japan. J Med Virol. 2003;69:441-446. Abstract
23. Kimbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol. 1993;67:6929-6936.
24. Kanda T, Onda T, Zanma S, et al. Independent association of antibodies against HPV type 16 E1/E4 and E7 proteins with cervical cancer. Virology. 1992; 190:724-732.
25. Hoffmann RG. Statistics in the practice of medicine. JAMA. 1963; 185:864-873.
26. Matsumoto K, Yoshikawa H, Taketani Y, et al. Antibodies to human papillomavirus 16, 18, 58 and 6b major capsid proteins among Japanese females. Jpn J Cancer Res. 1997;88:369-375.
27. Agliano AM, Gradiloone A, Gazzaniaga P, et al. High frequency of human papillomavirus detection in urinary bladder cancer. Urol Int. 1994;53:125-129.
28. Badawi H, Helmy A, Tosson W, et al. Study of sTRAIL, TNF-alpha in serum and ultrastructural apoptotic changes in buffy coat cells in viral or chlamydial cystitis and cancer bladder cases. Egypt J Med Microbiol. 2002;11:877-888.
29. Mvula M, Iwasaka T, Iguchi A, et al. Do human papillomavirus have a role in the pathogenesis of bladder carcinoma. J Urol. 1996;155:471-474.
30. Westenend PJ, Stoop JA, Hendriks JG. Human papillomaviruses 6/11, 16/18 and 31/33/51 are not associated with squamous cell carcinoma of the urinary bladder. Br J Urol Int. 2001;88:198-201.
31. Barghi MR, Hajimohammadmehdiarbab A, Moghaddam SM, et al. Correlation between human papillomavirus infection and bladder transitional cell carcinoma. BMC Infect Dis. 2005;5:1-5.
32. Chan WK, Wong KY, Srivastava G. Prevalence of human papillomavirus in inverted papilloma and papillary transitional cell carcinoma of the bladder: an evaluation by polymerase chain reaction. J Clin Pathol. 1997;50:1018-1021.
33. Sur M, Cooper K, Allard U. Investigation of human papillomavirus in transitional cell carcinoma of the urinary bladder in South Africa. Pathology. 2001;33:17-30.
34. Youshya S, Purdie K, Breuer J, et al. Does human papillomavirus play a role in the development of bladder transitional cell carcinoma? A cmparison of PCR and immunohistochemical analysis. J Clin Pathol. 2005; 58:207-210.
35. Anwar K, Nakakuki K, Shiraishi T, et al. Presence of ras oncogenic mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res. 1992;52:5991-6000.
36. Furihata M, Ohtsuki Y, Ogoshi S, et al. Prognostic significance of human papillomavirus genomes (type-16, 18) and aberrant expressin of protein in human esophageal cancer. Int J Cancer. 1993;54:226-230.
37. Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;209-216.
38. Reznikoff CA, Belair CD, Yeager TR, et al. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol. 1996;23:571-584.
39. Hagensee ME. Human papillomavirus vaccine. Infect Urol. 1999; 12:11-19.
40. Helal T, Fadel M, El-Sayed N. Human papillomavirus and p53 expression in bladder cancer in Egypt: relationship to schistosomiasis and clinicopathologic factors. Path Oncol Res. 2006; 12:173-178.
41. Le Cann P, Touze A, Enogant N, et al. Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay x4inant HPV 16 11 capsidtproduced by r 4382.':Abstract baculovirus. J ClhUctobiol. 42. Carter JJ, Koutsky LA, Hughes JP. Comparison of human papillornavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181:1911-1919.
42. Dillner J. Serology of human papillomavirus. Cancer J. 1995;85:264-267.
43. Touze A, De Sanjose S, Coursaget P, et al. Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol. 2001;39:4344-4348.
44. Gazzaniga P, Vercillo, R, Gradilone A, et al. Prevalence of papillomavirus, Epstein-Barr virus, cytomegalovirus, and herpes simplex virus type 2 in urinary bladder cancer. J Med Virol. 1998;55:262-267.
45. Ho GYF, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-428.
46. Petter A, Heim K, Guger M, et al. Specific serum IgG, IgM, and IgA antibodies to human papillomavirus-types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women. J. Gen Virol. 2000;81:701-708.
47. Heino, P, Eklund C, Fredriksson-Shahnazarian V, et al. Association of serum IgG antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst. 1995;87:437-440.
48. Hopfl R, Heim K, Christensen N, et al. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet. 2000;356:1985-1986.
49. Dubin G. Program and abstracts of the 22nd International Papillomavirus Conference and Clinical Workshop; April 30-May 6, 2005; Vancouver, British Columbia, Canada. Oral Communication F-03. Human papillomavirus vaccines to protect against cervical cancer.
50. Lippman A, Melnychuk R, Shimmin C, et al. Human papillomavirus, vaccines and women's health: questions and cautions. CMAJ. 2007;177:484-487.